INTERIM REPORT JANUARY-MARCH 2010

- Net revenue amounted to SEK 4.8 million (4.8)*
- The net loss totaled SEK 4.7 million (4.5)
- Earnings per share amounted to SEK -0.08 (-0.08)
- Product sales to end-customers and distributors were equivalent to 51% (24) of product sales
- Sales of Artelon® Spacer totaled SEK 2.6 million (3.5)
- Sales of Artelon® Tissue Reinforcement amounted to SEK 2.1 million (1.3)

N. B. This is a translation from Swedish. The Swedish version shall always take precedence.

Artimplant will not hold a telephone conference by reason of this report. For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

Artimplant
Degradable Materials for Optimal Tissue Repair

Artimplant

Artimplant's mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal.

Artimplant is a medical technology company that restores health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products are made from Artelon®, a biomaterial developed by the Company. Artimplant produces implants for the treatment of osteoarthritis in hands and feet, shoulder and other soft tissue injuries as well as oral and veterinary applications. The Company's products are sold through licensees and own sales under the Artimplant brand take place through agents and distributors.

Artelon® CMC/STT Spacer

Artimplant's first product, which is used to treat osteoarthritis (wearing of the cartilage) in the thumb base joint. The product has been granted regulatory clearance and has been launched in Europe, the USA and a small number of other countries.

Artelon® MTP Spacer

Product for the treatment of osteoarthritis in the big toe joint. The product is in the launch phase in Europe.

Artelon® Tissue Reinforcement

The product is a mesh used as reinforcement in conjunction with the repair of soft tissue e.g. tendons. The product is currently in the market introduction phase in Europe and the USA.

Artelon® Cosmetic

A product for soft tissue augmentation in the mouth. Approved for sale in Europe.

Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the Healthcare sector.



Introduction

Artimplant's sales for the first quarter are on a par with the previous year. Own sales continue, as planned, to increase and now account for half of the revenue. Artimplant has not had any sales to Biomet Sports Medicine during the first quarter as they have sold from their own inventory. Licensees' sales to end-customers are otherwise on the same level as during the fourth quarter of 2009.

In February, Artimplant was an exhibitor at the world's largest orthopedic congress, the American Academy of Orthopaedic Surgeons, AAOS. At the congress, American medical practitioners presented positive results for Artelon® CMC Spacer. These data are an important source of support if licensees are to regain lost sales volumes.

Artelon® Tissue Reinforcement continues to convince surgeons and patients of its user-friendliness and positive treatment outcome. Artimplant's primary growth is planned to take place through increased own sales, mainly in the USA. The majority of the growth in sales is expected to take place in line with the commencement of sales through new agents. During the quarter, the majority of agents received basic training in Artimplant's products. To improve conditions for our market expansion, it has been decided to increase Artimplant's presence in the USA and, among other things, employ product specialists to increase sales support and to prepare for future product launches.

The Company's focus on new applications for the unique Artelon® platform continues. In addition to the existing product portfolio, the possibility of manufacturing a product at the interface between sutures and ATR is investigated. The plan is, using an unchanged development plan and greater marketing intensity, to achieve both short-term and long-term revenue growth.

Financial results

Net revenue amounted to SEK 4.8 million (4.8). Net revenue was primarily from revenue from product sales and 49% (76) of revenue originated from licensees and 51% (24) from own sales via agents and Artimplant's own local distributors.

The gross margin for product sales during the first quarter was 81% (95). During the first quarter the production volume was low and the Group's inventory fell by SEK 0.2 million. The gross margin during the first quarter of the 2009 comparison period was affected positively by a high production volume, which produced a net increase in the Group's inventory of SEK 0.6 million.

The operating loss for the first quarter amounted to SEK 4.7 million (4.6). Operating expense, excluding the cost of goods and services sold as well as the stated non-recurring items, was SEK 0.8 million lower than the corresponding period the preceding year. This can be attributed mainly to the fact that depreciation of capitalized product development costs for Artelon® CMC Spacer of approximately SEK 0.5 million per quarter was concluded during 2009.

The net loss for the first quarter was SEK 4.7 million (4.5) including a marginal currency exchange rate fluctuation after tax of SEK 0.0 million (0.1). Earnings per share for the first quarter were SEK -0.08 (-0.08).

Seasonal effects

Artimplant has not been exposed to any material seasonal effects, neither in revenue nor in costs.

Investments and cash position

Investments during the first quarter totaled SEK 0.1 million (0.1), of which SEK 0.1

million (0.1) was attributable to intangible assets.

At the end of the period cash and cash equivalents amounted to SEK 12.9 million (25.1). Total cash flow for January-March amounted to SEK -2.7 million (-6.3). The total change in operating capital was positive, amounting to SEK 1.7 million (-2.8). The main positive contribution has been from receivables.

The Company has access to an operating capital credit facility of SEK 8.0 million. As of the date of this report SEK 4.0 million of this credit facility has been utilized. The remainder of the credit is available through a bank overdraft facility. A chattel mortgage for SEK 8.0 million has been furnished as collateral.

Personnel

As of March 31, 2010, Artimplant had 25 employees (28), of whom 13 (15) were women and 12 (13) were men.

Market development

During the fourth quarter Artimplant USA commenced the expansion of the distributor network. Around 15 new agents have been contracted. Training of these agents commenced in January 2010 and their sales have begun at a number of new hospitals. Artimplant is now represented in the majority of the states in the USA through more than 30 agents. In Europe, Artimplant is not planning to make any changes and the focus will be on working through existing distributors. During the first quarter, own sales totaled SEK 2.4 million (1.2).

Artelon® Spacer is a product for the treatment of osteoarthritis in a number of joints in the hand and foot. Sales revenue from Artelon® Spacer during the first quarter amounted to SEK 2.6 million (3.5). The licensee, Small Bone Innovations (SBi), accounts for the majority of sales. During the first quarter, sales of Artelon® CMC Spacer were generally stable on all markets. During the third quarter of 2009, US sales of Artelon® CMC Spacer declined following reports of unsatisfactory surgical outcomes. This is attributable to isolated procedures during the immediate post-launch period where user instructions were not followed. This led to two negative case reports being published in the Journal of Hand Surgery. SBi and Artimplant are currently working on corrective communications to surgeons, including the publication of new data confirming the medical benefit of the product and stressing the vital importance of compliance with user instructions.

Artelon® Tissue Reinforcement (ATR) has been cleared as general reinforcement for soft tissue injuries. It is sold non-exclusively by the licensee Biomet Sports Medicine as SportMesh™. Artimplant's sales revenue from ATR and SportMesh™ during the first quarter totaled SEK 2.1 million (1.3). Biomet Sports Medicine has sold primarily from its own inventory during the first quarter. The majority of these ATR sales come from direct sales via agents in the USA. During the first quarter, Artimplant's direct sales via agents and sales via local distributors rose quickly and thus accounted for an increasingly higher proportion of the Company's total sales for this product group. Artimplant is working on employing local product specialists and publishing clinical studies and case reports. These activities are expected to contribute to a continued increase in market penetration.

Product and business development

The Schulthess Clinic in Zurich is conducting a clinical pilot study of Artelon® implants. The aim of this study is to document safety and user-friendliness in the treatment of painful osteoarthritis in the facet joints in the spine with Artelon®. Pain relief with this treatment will be investigated and the patients

will be followed up over a two-year period. The Schulthess Clinic commenced the study during the second quarter of 2009 when the first patient was enrolled. Patient inclusion in the study is proceeding according to plan.

Artimplant and Tulsa Bone & Joint Associates, Tulsa, Oklahoma, USA, are running a post-market study of ATR for patients with tears in the rotator cuff tendons. The study comprises approximately 20 patients. The final patient underwent surgery in October 2009, whereupon a one-year follow-up commenced.

Artimplant is investing in a number of studies involving Artelon® MTP Spacer. A Swedish investigator-initiated, multicenter study is in progress on the treatment of stiff big toe (*Hallux Rigidus*) using Artelon® MTP Spacer. The final patient underwent surgery in May 2009, whereupon a one-year follow-up commenced. A further study is planned at Sahlgrenska University Hospital. The product satisfies an obvious clinical need as at present there are no effective, established treatment methods available for these patients.

A post-market study has been conducted by the Brånemark Clinic in Gothenburg regarding Artelon® Cosmetic for replenishment of soft tissue in dental applications. The study results which confirm the clinical function of the product have been compiled and will be published.

In 2008, the Swedish Medical Products Agency gave the go-ahead for a study of Artelon® Bone Scaffold with the aim of securing regulatory clearance for the product. The product will be used for bone replenishment in the upper jaw in conjunction with the fitting of dental implants. The study is being conducted in co-operation with Swedish oral surgery experts. All patients in the study have now undergone surgery with Artelon® Bone Scaffold and have received dental implants. The long-term function of the product will be followed up during 2010.

In collaboration with SBi, Artimplant is developing a new Artelon® CMC Spacer based on the same textile design as ATR, which is expected to contribute to improved user-friendliness.

In cooperation with Swedish veterinary experts, Artelon® has been used successfully in the treatment of cruciate ligament injuries in dogs. By using Artelon® as an artificial ligament (Artelon® CCL) conditions are created for the body to restore a functional ligament. An investigation with a one-year follow-up of the surgical results will be concluded during 2010. Positive results from the study will create an important basis for future market penetration.

In cooperation with American veterinary experts and Artimplant's veterinary medicine distributor BioMedtrix, Artimplant has planned a prospective investigation with Artelon® CCL in the USA. Prior to the study a biomechanical evaluation was carried out. The evaluation has led to a second-generation product design and an improved surgical procedure. The first dogs subsequently underwent surgery in the CCL study. Inclusion is continuing according to plan. The plan is for all dogs to undergo surgery during 2010, whereupon a one-year follow-up will commence. Successful results are a prerequisite for the future launch of Artelon® CCL in the USA.

Artimplant's products and projects can be viewed in four phases: concept evaluation/proof-of-concept (Explore), product development and documentation for market registration (Develop), launch and post-market studies (Market Introduction) and a product established on the market (Established).

Product Concept	Intended use	Product	Explore	Develop	Market Intro.	Established
Resurfacing	Osteoarthritis in the thumb base joint	Artelon® CMC/ STT Spacer				
	Osteoarthritis in the big toe joint	Artelon® MTP Spacer*				
	Osteoarthritis in the facet joints of the lumbar spine	Facet Spacer				
	Osteoarthritis in the knee joint	Knee Resurfacing				
Reinforcement	Soft tissue reinforcement of tendons and ligaments	Artelon® Tissue Reinforcement				
	Knee ligament reconstruction in dogs	Artelon® CCL				
Replenishment	Soft tissue augmentation in the mouth	Artelon® Cosmetic*				
	Bone augmentation in the upper jaw	Artelon® Bone Scaffold				

* Not cleared for sale in the USA

During 2009, Artimplant also evaluated the use of Artelon® for soft tissue reinforcement of, among other things, the Achilles tendon in dogs. The results from a minor case study in the USA have been compiled for presentation at a scientific symposium. Marketing has commenced on a small-scale and ten or so centers have notified an interest in participating in a multicenter study.

Future prospects

The plan is for the Company's growth during 2010 to be achieved through increased own sales of existing products within orthopedics. Artimplant's direct sales in the USA will account for the majority of the growth in sales, which are expected to increase gradually as new agents begin selling and building up confidence in Artimplant's products in each sales district. The Company does not provide a forecast of the rate at which the sales will increase although Artimplant works towards the goal of reaching positive cash flow before changes in working capital, at a monthly basis, towards the end of 2010.

Artimplant's business operations are based on exploiting the Company's unique biomaterial platform Artelon®. The orthopedic areas hip, knee and spine offer the greatest market potential. Artimplant intends to continue investing in projects in these areas at the same

time that the scientific base is reinforced for cleared products, which offers support for increased sales.

Significant risks and uncertainty factors

The Company's significant risks and uncertainty factors are presented in the Board of Directors' Report in the most recent annual report. These have not changed to any material extent.

Parent Company

The majority of Artimplant's operations are run through the Parent Company, Artimplant AB. Artimplant USA, Inc. is the Company's only subsidiary and is at present fully funded by the Parent Company. The Parent Company is responsible for continuity at the subsidiary and during the first quarter of 2010 an impairment was made of receivables from Artimplant USA totaling SEK 0.9 million. Together with the provision of SEK 9.0 million in the opening balance, the total impairment is SEK 9.9 million, which is equivalent to the subsidiary's negative equity. The impairment does not affect the Group result. The difference in the Parent Company's equity compared with the Group's equity can be explained by the internal profit on products sold by the Parent Company to the subsidiary and amounts to SEK 9.1 million. The aim is that the subsidiary will become self-financing during the second quarter of 2010 and thus commence amortization of its liabilities to the Parent Company. See summary of the Parent Company Statement of Comprehensive Income and Statement of Financial Position on pages 11-12.

Accounting principles

Artimplant applies IFRS. This interim report has been prepared in accordance with IAS 34, the Swedish Annual Accounts Act and RFR 1.3. The Parent Company's financial statements are prepared in accordance with exceptions and addenda in RFR 2.3. No new or amended IFRS which came into effect in 2010 had any significant impact on the Group.

The reclassification in the accounting records of currency effects, which was made in the third quarter 2009, has been taking into account in this report in the comparison figures for the first quarter of 2009.

Further accounting principles can be found in the Company's Annual Report for 2009, which is available on the Company's website.

Forthcoming information

Three-monthly report	May 4, 2010
Six-monthly report	August 3, 2010
Nine-monthly report	October 28, 2010
Year-end report	February 10, 2011
Three-monthly report	May 4, 2011

Financial reports are available on the Company's website www.artimplant.com and are also distributed to the media. For information regarding the business model, technology and products, see Artimplant's Annual Report for 2009, which is available on the Company's website.

For further information please contact

Hans Rosén, Chief Executive Officer
Tel + 46 31 746 56 44, +46 708 583 470
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO
Tel. +46 31 746 56 54, +46 703 016 854
lars-johan.cederbrant@artimplant.com

Artimplant AB
Hulda Mellgrens gata 5
SE-421 32 Västra Frölunda
Sweden

Telephone +46 (0)31 746 56 00
Fax +46 (0)31 746 56 60
Web www.artimplant.com
Reg. No. 556404-8394
Reg. office: Municipality of Gothenburg, County of Västra Götaland

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Amounts in KSEK	Jan-Mar 2010	Jan-Mar 2009	Jan-Dec 2009
Net sales	4,756	4,848	23,998
Cost of goods and services sold	-977	-232	-4,328
Gross profit/loss	**3,779**	**4,616**	**19,670**
Other income	72	344	451
Research and development costs (1, 2)	-3,515	-4,204	-14,995
Selling costs	-3,585	-3,768	-17,049
Administrative costs	-1,448	-1,377	-5,729
Other costs	-49	-217	-861
Operating loss	**-4,746**	**-4,606**	**-18,513**
Interest income and other financial income	59	117	311
Interest expense and other financial expenses	-56	3	-431
Net financial items	**3**	**120**	**-120**
Loss after financial items	**-4,743**	**-4,486**	**-18,633**
Taxes	-	-	-
Loss for the period*	**-4,743**	**-4,486**	**-18,633**
Loss attributable to the Parent Company's stockholders	-4,743	-4,486	-18,633
Earnings per stock unit, SEK	-0.08	-0.08	-0.31
Earnings per stock unit after dilution, SEK	-0.08	-0.08	-0.31

** Same as the comprehensive income for the period*

The statements include depreciation of tangible fixed assets and amortization of intangible fixed assets as shown in the following table.

Amounts in KSEK	Jan-Mar 2010	Jan-Mar 2009	Jan-Dec 2009
(1) Capitalized R&D cost	-	546	1,635
(2) Patents and brands	185	222	866
Machinery and equipment	121	152	610
Total depreciation	**306**	**920**	**3,111**

ALLOCATION OF CONSOLIDATED NET SALES

Amounts in KSEK Source of revenue	Jan-Mar 2010	Jan-Mar 2009	Jan-Dec 2009
Product sales by licensees	2,283	3,686	14,572
Product sales by end customer and distributors	2,382	1,159	8,680
One-off and project milestone income	-	-	-
Contract product development and other sales	90	3	746
	4,756	**4,848**	**23,998**

Geographic areas	Jan-Mar 2010	Jan-Mar 2009	Jan-Dec 2009
North America	4,341	4,217	18,705
Europe	415	631	5,041
Other areas	-	-	252
	4,756	**4,848**	**23,998**

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Amounts in KSEK	3/31/2010	3/31/2009	12/31/2009
ASSETS			
Capitalized product development	1,191	2,280	1,191
Patents and brands	1,482	2,405	1,587
Total intangible fixed assets	*2,673*	*4,685*	*2,778*
Machinery and equipment	606	1,166	723
Total tangible fixed assets	*606*	*1,166*	*723*
Total fixed assets	**3,279**	**5,851**	**3,501**
Raw materials, semi-finished and finished goods	3,978	5,303	4,137
Total inventories, etc.	*3,978*	*5,303*	*4,137*
Accounts receivable	1,481	537	2,946
Other receivables	1,161	1,145	1,014
Prepaid expenses and accrued income	2,322	4,878	3,286
Total short-term receivables	*4,964*	*6,560*	*7,247*
Cash and bank accounts	12,922	25,122	15,613
Total current assets	**21,864**	**36,985**	**26,997**
TOTAL ASSETS	**25,143**	**42,836**	**30,498**

Amounts in KSEK	3/31/2010	3/31/2009	12/31/2009
STOCKHOLDERS' EQUITY & LIABILITIES			
Capital stock	5,924	5,924	5,924
Other capital reserves	39,953	58,270	39,953
Retained loss	-21,890	-22,112	-3,390
Translation difference	-	-	-
Loss for the period	-4,743	-4,486	-18,633
Total equity	**19,244**	**37,596**	**23,853**
Provisions	**76**	**26**	**65**
Accounts payable	781	890	1,147
Other current liabilities	349	1,240	1,393
Accrued expenses and prepaid income	4,693	3,084	4,040
Total current liabilities	**5,823**	**5,214**	**6,579**
TOTAL STOCKHOLDERS' EQUITY & LIABILITIES	**25,143**	**42,836**	**30,498**

CONSOLIDATED CHANGES IN STOCKHOLDERS' EQUITY DURING THE PERIOD

Amounts in KSEK	Jan-Mar 2010	Jan-Mar 2009	Jan-Dec 2009
Capital stock	**5,924**	**5,924**	**5,924**
Other capital reserves at the beginning of the period*	39,953	58,270	58,270
Reduction in other capital reserves	-	-	-18,317
Total other capital reserves	**39,953**	**58,270**	**39,953**
Retained loss at the beginning of the period	-22,024	-22,229	-22,229
Reduction in other capital reserves	-	-	18,317
Benefit, employee stock option (IFRS 2)	134	117	521
Loss for the period	-4,743	-4,486	-18,633
Total retained loss	**-26,633**	**-26,598**	**-22,024**
Equity at the period-end	**19,244**	**37,596**	**23,853**

** Other capital reserves have been reduced annually to cover the retained loss.*
Total other capital reserves before issue costs amount to SEK 438 million.

CONSOLIDATED CASH FLOW STATEMENTS

Amounts in KSEK	Jan-Mar 2010	Jan-Mar 2009	Jan-Dec 2009
Operating activities			
Net loss after financial items	-4,743	-4,486	-18,633
Adjustment for items not effecting cash flow	449	1,035	3,974
Cash flow from operations before changes in working capital	**-4,294**	**-3,451**	**-14,659**
Cash flow from changes in working capital			
Changes in inventories etc.	159	-577	589
Changes in receivables	2,283	-2,329	-3,035
Changes in liabilities	-759	125	1,576
Cash flow from operations	**-2,611**	**-6,232**	**-15,529**
Investment activities			
Acquisition of intangible fixed assets	-80	-57	-215
Acquisition of tangible fixed assets	-	-10	-25
Sale of tangible fixed assets	-	8	11
Cash flow from investment activities	**-80**	**-59**	**-229**
Financing activities			
Cash flow from financing activities	**-**	**-**	**-**
Cash flow for the period	**-2,691**	**-6,291**	**-15,758**
Cash and cash equivalents at the beginning of the per	**15,613**	**31,371**	**31,371**
Translation of foreign liquid assets	**-**	**42**	**-**
Cash and cash equivalents at the period-end	**12,922**	**25,122**	**15,613**

CONSOLIDATED KEY RATIOS

	Jan-Mar 2010	Jan-Mar 2009	Jan-Dec 2009
Earnings per stock unit, SEK	-0.08	-0.08	-0.31
Earnings per stock unit after dilution, SEK	-0.08	-0.08	-0.31
Equity per stock unit, SEK	0.32	0.63	0.40
Equity per stock unit after dilution, SEK	0.32	0.63	0.40
No. of stock units in issue at the period-end	59,244,790	59,244,790	59,244,790
Average no. of stock units in issue during period	59,244,790	59,244,790	59,244,790
No. of stock units in issue after dilution	61,346,566	60,793,245	61,346,566
Cash flow per stock unit, SEK	-0.05	-0.11	-0.27
Operating margin, %	neg	neg	neg
Return on equity, %	neg	neg	neg
Return on capital employed, %	neg	neg	neg
Return on capital, %	neg	neg	neg
Equity/assets ratio, %	77	88	78

PARENT COMPANY INCOME STATEMENTS

Amounts in KSEK	Jan-Mar 2010	Jan-Mar 2009	Jan-Dec 2009
Net sales	4,403	5,621	28,192
Cost of goods and services sold	-994	-326	-4,554
Gross profit/loss	**3,409**	**5,295**	**23,638**
Other income	487	1,477	2,151
Research and development costs (1,2)	-3,515	-4,204	-14,995
Selling costs	-2,156	-2,786	-12,203
Administrative costs	-1,448	-1,377	-5,729
Other costs	-377	-922	-3,345
Operating loss	**-3,600**	**-2,517**	**-10,483**
Interest income and other financial income	205	938	1,360
Interest expense and other financial expenses	-169	-460	-1,781
Impairment of receivebles subsidiaries	-857	-1,493	-2,898
Net financial items	**-821**	**-1,015**	**-3,319**
Loss after financial items	**-4,421**	**-3,532**	**-13,802**
Taxes	-	-	-
Loss for the period*	**-4,421**	**-3,532**	**-13,802**

** Same as the comprehensive income for the period*

The income statements include depreciation of tangible fixed assets and amortization of intangible fixed assets as shown in the following table.

Amounts in KSEK	Jan-Mar 2010	Jan-Mar 2009	Jan-Dec 2009
(1) Capitalized R&D cost	-	546	1,635
(2) Patents and brands	185	222	866
Machinery and equipment	117	150	603
Total depreciation	**302**	**918**	**3,105**

PARENT COMPANY BALANCE SHEETS

Amounts in KSEK	3/31/2010	3/31/2009	12/31/2009
ASSETS			
Total intangible fixed assets	*2,673*	*4,685*	*2,778*
Total tangible fixed assets	*598*	*1,153*	*715*
Stock and participation in subsidiaries	10	10	10
Total fixed assets	**3,281**	**5,848**	**3,503**
Total inventories, etc.	*3,660*	*5,066*	*3,825*
Accounts receivable	209	308	1,923
Receivables from affiliated companies	10,641	5,195	9,736
Other receivables	1,161	1,145	1,014
Prepaid expenses and accrued income	2,307	4,930	3,162
Total short-term receivables	*14,318*	*11,578*	*15,835*
Cash and bank accounts	12,531	24,867	15,020
Total current assets	**30,509**	**41,511**	**34,680**
TOTAL ASSETS	**33,790**	**47,359**	**38,183**

Amounts in KSEK	3/31/2010	3/31/2009	12/31/2009
STOCKHOLDERS' EQUITY & LIABILITIES			
Total equity	**28,308**	**42,462**	**32,596**
Provisions	**76**	**26**	**65**
Total current liabilities	**5,406**	**4,871**	**5,522**
TOTAL STOCKHOLDERS' EQUITY & LIABILITIES	**33,790**	**47,359**	**38,183**

The Board of Directors and the CEO certify that this Report provides a true and fair overview of the Parent Company's and the Group's operations, financial position and results and presents the material risks and uncertainty factors facing the Parent Company and the companies that form part of the Group.

Gothenburg, May 4, 2010
Artimplant AB (publ)

Ingemar Kihlström
Chairman of the Board

Hans Rosén
CEO

Mats Lindquist
Board Member

Lennart Ribohn
Board Member

Wenche Rolfsen Sandsborg
Board Member

Anna Malm Bernsten
Board Member

This report has not been reviewed by the Company's auditors.

This information is information which Artimplant is required to publish pursuant to the Swedish Financial Instruments Act and/or the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. The information was published on May 4, 2010 at 3 pm (CET).

History

1986 – 1996 - A medical need is identified and the development of a new biomaterial commences. During subsequent years material, product and production development takes place and the technology is verified through preclinical trials.

1997 - The Company acquires a Swedish patent for Artelon® hydrolyzable fiber polymers for use in temporary implants. The Company is floated on the Stockholm Stock Exchange. The first cruciate ligament (ACL) operations on human patients using implants from Artimplant are carried out within the framework of a pilot study.

1998 - The Company acquires Gothenburg Medical Center, a clinic specializing in sports-related injuries.

1999 - Pilot studies in the treatment of damaged thumb ligament and thumb base osteoarthritis are initiated. Artimplant's first multicenter trial in ACL reconstruction begins. Artimplant begins cooperation with Mölnlycke Health Care AB in the field of wound care.

2000 - The first multicenter trial in ACL reconstruction is concluded. The second multicenter ACL reconstruction trial begins. Artimplant's Artelon® patent is approved in the USA and Europe. The marketing organization is expanded.

2001 - Artimplant's quality assurance system is certified by Lloyds Register Quality Assurance. Artimplant's first product, the Artelon® Augmentation Device ACL is granted CE-certification and can now be marketed in Europe. The task of building up the Company's own marketing and sales organization ceased during the autumn. Products and material technology will be commercialized through the granting of licenses to leading companies with a global presence.

2002 - Agreement on wound care signed with Mölnlycke Health Care AB. An extensive restructuring program is commenced to reduce the Company's cost base.

2003 - The Company signs an agreement with Atlantech for sales in the UK of its Artelon® Augmentation Device ACL. Artimplant's Artelon® CMC Spacer for treating thumb base osteoarthritis receives clearance for marketing in Europe. Artelon® Surgical Suture is given clearance by the FDA for sales on the American market. The subsidiary Gothenburg Medical Center is sold.

2004 - Artelon® CMC Spacer receives clearance for marketing from the FDA for sales on the US market. Licensing agreements signed with Small Bone Innovations. A licensing agreement is signed with Biomet Inc. for the production of SportMesh™. Cooperation with Atlantech for the sale of Artelon® Augmentation Device ACL is concluded. Cooperation between Artimplant and Mölnlycke Health Care within wound care is concluded.

2005 - Four new licensing and development agreements are signed with Small Bone Innovations. A distribution agreement for Artelon® Surgical Suture in North America is signed with ArthroCare. Artelon® implant for reinforcing rotator cuffs is cleared for marketing in Europe. Office opened in the United States.

2006 - The Company receives clearance for marketing by the FDA for the sale of the SportMesh™ rotator cuff implant in the USA. Four new Spacer products for the treatment of osteoarthritis in the hand and foot are granted clearance for marketing in Europe. The product Artelon® Augmentation Device ACL is discontinued. Sales of Artelon® CMC Spacer to end-customers increase significantly.

2007 - The Company's sales increase markedly and cash flow improves considerably. The FDA grants clearance to market Artelon® Tissue Reinforcement for soft tissue reinforcement in several new indications in the USA. Two new Spacer products for osteoarthritis in the hand are granted clearance by the FDA for marketing in the USA.

2008 - Sales of Artelon® Tissue Reinforcement increase significantly whilst there is a lack of growth in sales of Artelon® Spacer. Artimplant is initiating new development projects for the treatment of knee joint osteoarthritis and osteoarthritis in the facet joint in the spine. Agreement signed with BioMedtrix regarding the distribution in the USA of Artelon® CCL for cruciate ligament reconstruction in dogs.

2009 - Sales double and product sales to end-customers and distributors multiply, increasing its share of total sales to 37% (15). The agreement with Small Bone Innovations is renegotiated, making it non-exclusive from 2009. All patients are enrolled for the American post-market study of Artelon® Tissue Reinforcement for the treatment of patients with tears in the rotator cuff tendons. The first patients are included in a clinical study for the treatment of osteoarthritis in the facet joint in the spine with an Artelon® implant. Product design and procedure are developed further for Artelon® CCL. The first dogs in a prospective investigation in the USA undergo cruciate ligament reconstruction using Artelon® CCL.